AC Immune

AC Immune

Yahoo Finance • 11 days ago

AC Immune First Half 2026 Financial and Corporate Update

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-t... Full story

Yahoo Finance • 4 months ago

AC Immune First Quarter 2026 Financial and Corporate Updates

AC Immune SA AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 In... Full story

Yahoo Finance • 4 months ago

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone paymentAllows evalua... Full story

Yahoo Finance • 4 months ago

Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great News

AC Immune SA (NASDAQ:ACIU) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 7, 2026, Leerink analyst Marc Goodman said AC Immune SA (NASDAQ:ACIU) amending its collaboration with Eli Lilly for the Morphomer Tau progra... Full story

Yahoo Finance • 4 months ago

Eli Lilly Extends AC Immune Tau Pact To Broaden Alzheimer’s Pipeline Potential

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly (NYSE:LLY) and AC Immune have amended their collaboration focused on Tau aggregation inhibitor small molecules fo... Full story

Yahoo Finance • 4 months ago

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

AC Immune Announces Amendment to Morphomer® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer sma... Full story

Yahoo Finance • 5 months ago

AC Immune GAAP EPS of -CHF0.70, revenue of CHF3.57M

* AC Immune press release [https://seekingalpha.com/pr/20436508-ac-immune-reports-full-year-2025-financial-results-and-provides-a-corporate-update] (ACIU [https://seekingalpha.com/symbol/ACIU]): FY GAAP EPS of -CHF0.70. * Revenue of CH... Full story

Yahoo Finance • 10 months ago

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative diseases including ALS, FT... Full story

Yahoo Finance • 11 months ago

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30%Increased... Full story

Yahoo Finance • last year

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical developmentACI-7104.056 anti-alpha-syn... Full story

Yahoo Finance • last year

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on averag... Full story

Yahoo Finance • last year

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention... Full story

Yahoo Finance • last year

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 bil... Full story

Yahoo Finance • 3 years ago

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune SA AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal app... Full story

Yahoo Finance • 3 years ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative... Full story

Yahoo Finance • 3 years ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE Phase 1b/2 study on track for H1 2024AC... Full story

Yahoo Finance • 3 years ago

We're Not Very Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, y... Full story

Yahoo Finance • 3 years ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmac... Full story

Yahoo Finance • 3 years ago

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

PRESSRELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the first element of a precision medicine approac... Full story

Yahoo Finance • 3 years ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative d... Full story